


IN THE CLAIMS

1-19 (canceled)

20 (original) A hydroxyindole of formula 1,



wherein

n is 1 or 2, and

R¹

(i) is -C₁₋₁₀-alkyl, which is straight-chain or branched and optionally substituted, once or more than once, by -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC₆₋₁₄aryl, -N(C₆₋₁₄aryl)₂, -N(C₁₆alkyl)(C₆₋₁₄aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -O-C₆₋₁₄-aryl, -S-C₁₋₆-alkyl, -S-C₆₋₁₄aryl, -SO₃H, -SO₂C₁₋₆alkyl, -SO₂C₆₋₁₄aryl, -OSO₂C₁₋₆alkyl, -OSO₂C₆₋₁₄aryl, -COOH, -(CO)C₁₋₅alkyl or -O(CO)C₁₋₅alkyl, by mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated carbocycles having 3-14 ring members, or by mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated heterocycles having 5-15 ring members and 1-6 heteroatoms which are preferably N, O and S, where the

C₆₋₁₄aryl groups and the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by -C₁₋₆-alkyl, -OH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, -SO₃H, -SO₂C₁₋₆alkyl, -OSO₂C₁₋₆alkyl, -COOH, -(CO)C₁₋₅alkyl or -O(CO)C₁₋₅alkyl, and where the alkyl groups on the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or -COOH, or

(ii) is -C₂₋₁₀-alkenyl, which is monounsaturated or polyunsaturated, straight-chain or branched and optionally substituted, once or more than once, by -OH, -SH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NHC₆₋₁₄aryl, -N(C₆₋₁₄aryl)₂, -N(C₁₋₆alkyl)(C₆₋₁₄aryl), -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -O-C₆₋₁₄-aryl, -S-C₁₋₆-alkyl, -S-C₆₋₁₄aryl, -SO₃H, -SO₂C₁₋₆alkyl, -SO₂C₆₋₁₄aryl, -OSO₂C₁₋₆alkyl, -OSO₂C₆₋₁₄-aryl, -COOH, -(CO)C₁₋₅-alkyl or -O(CO)C₁₋₅alkyl, by mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated carbocycles having 3-14 ring members, or by mono-, bi- or tricyclic saturated or monounsaturated or polyunsaturated heterocycles having 5-15 ring members and 1-6 heteroatoms which are preferably N, O and S, where the C₆₋₁₄aryl groups and the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by -C₁₋₆-alkyl, -OH, -NH₂, -NHC₁₋₆-alkyl, -N(C₁₋₆-alkyl)₂, -NO₂, -CN, -F, -Cl, -Br, -I, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, -SO₃H, -SO₂C₁₋₆alkyl, -OSO₂C₁₋₆alkyl, -COOH, -(CO)C₁₋₅alkyl or -O(CO)C₁₋₅alkyl, and where the alkyl groups on the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by -OH, -SH, -NH₂, -F, -Cl, -Br, -I, -SO₃H or -COOH,

R² and R³

(i) are, in each case independently of each other, hydrogen or -C₁₋₅-alkyl,

which is optionally substituted, once or more than once, by $-\text{OH}$, $-\text{SH}$, $-\text{NH}_2$, $-\text{NHC}_{1-6}\text{-alkyl}$, $-\text{N}(\text{C}_{1-6}\text{-alkyl})_2$, $-\text{NO}_2$, $-\text{CN}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O-C}_{1-6}\text{-alkyl}$, $-\text{S-C}_{1-6}\text{-alkyl}$, $-\text{phenyl}$ or $-\text{pyridyl}$,

$-\text{phenyl}$,

which is optionally substituted, once or more than once, by $-\text{C}_{1-3}\text{-alkyl}$, $-\text{OH}$, $-\text{SH}$, $-\text{NH}_2$, $-\text{NHC}_{1-3}\text{-alkyl}$, $-\text{N}(\text{C}_{1-3}\text{-alkyl})_2$, $-\text{NO}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{COOC}_{1-3}\text{-alkyl}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O-C}_{1-3}\text{-alkyl}$, $-\text{S-C}_{1-3}\text{-alkyl}$ or $-\text{O}(\text{CO})\text{-C}_{1-3}\text{-alkyl}$,

$-\text{pyridyl}$,

which is optionally substituted, once or more than once, by $-\text{C}_{1-3}\text{-alkyl}$, $-\text{OH}$, $-\text{SH}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{COOC}_{1-3}\text{-alkyl}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O-C}_{1-3}\text{-alkyl}$, $-\text{S-C}_{1-3}\text{-alkyl}$ or $-\text{O}(\text{CO})\text{-C}_{1-3}\text{-alkyl}$,

where only one of R^2 and R^3 is hydrogen and where the alkyl groups on the carbocyclic and heterocyclic substituents can, for their part, be optionally substituted, once or more than once, by $-\text{OH}$, $-\text{SH}$, $-\text{NH}_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{SO}_3\text{H}$, $-\text{COOH}$, $-\text{O}(\text{CO})\text{-C}_{1-5}\text{-alkyl}$, or $-\text{O}(\text{CO})\text{C}_{1-5}\text{-alkyl}$, or

- (ii) NR^2R^3 together form a saturated or unsaturated five-membered or six-membered ring which can contain up to 3 heteroatoms, preferably N, S and O, and which is optionally substituted, once or more than once, by $-\text{C}_{1-3}\text{-alkyl}$, $-\text{OH}$, $-\text{SH}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{COOC}_{1-3}\text{-alkyl}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{O-C}_{1-3}\text{-alkyl}$, $-\text{S-C}_{1-3}\text{-alkyl}$ or $-\text{O}(\text{CO})\text{-C}_{1-3}\text{-alkyl}$,

R^4 and R^5 are $-\text{H}$ or $-\text{OH}$, where at least one of the two must be $-\text{OH}$, or salts of the compounds according to formula 1.

21. (original) A compound according to claim 20, wherein said compound has an asymmetric carbon atom in the D form or L form, or D,L mixtures or, when more than one asymmetrical carbon atom is present, the diastereomeric forms.
22. (original) A compound according to claim 20, wherein n is 2.
23. (original) A compound according to claim 20, wherein $R^4 = -OH$ and $R^5 = -H$.
24. (original) A compound according to claim 20, wherein $-NR^2R^3$ is a phenylamino or pyridylamino which is substituted by one or more halogen atoms.
25. (original) A compound according to claim 20, wherein R^1 is a substituted benzyl radical.
26. (original) A compound according to claim 25, wherein the benzyl radical contains at least one substituent in the ortho position on the phenyl ring.
27. (original) A compound according to Claim 20 selected from the group consisting
N-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-4-hydroxyindol-3-yl]carboxamide,
N-(3,5-dichloropyridin-4-yl)-[1-(4-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,
N-(3,5-dichloropyridin-4-yl)-[1-(4-chlorobenzyl)-7-hydroxyindol-3-yl]carboxamide,
N-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-4-hydroxyindol-3-yl]glyoxyamide,
N-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,
N-(3,5-dichloropyridin-4-yl)-[1-(2-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,
N-(3,5-dichloropyridin-4-yl)-[1-(3-nitrobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2,4-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2,6-dichlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2-methylbenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2,6-dimethylbenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-(1-hexyl-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-(1-isobutyl-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-(1-cyclopropylmethyl-7-hydroxyindol-3-yl]glyoxylamide,

N-(2,6-dichlorophenyl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(2,6-dichlorophenyl)-[1-(2-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(4-pyridyl)-[1-(2-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(4-pyridylmethyl)-7-hydroxyindol-3-yl]glyoxylamide,

1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylic acid piperidide,

N-(3,5-dichloropyridin-4-yl)-[1-(4-hydroxybenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2-chloro-6-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(3,5-dichloropyridin-4-yl)-[1-(2-trifluoromethylbenzyl)-7-hydroxyindol-3-yl]glyoxylamide,


N-methyl-N-(pyridin-4-yl)-[1-(2-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

N-(2,6-dimethylpyridin-4-yl)-[1-(2-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide,
and


N-(3,5-dichloropyridin-4-yl)-[1-(2-carboxybenzyl)-7-hydroxyindol-3-yl]glyoxylamide,

and physiologically tolerated salts thereof.

28. (original) A process for preparing a compound according to claim 20 comprising reacting an indole-3-carboxylic acid of formula 2:



with an acid chloride to form the analogous indole-3-carbonyl chloride of the formula 3




formula 3


reacting the compound of formula 3 with a primary and a secondary amine to form the corresponding amide and eliminating a protecting group to form a compound of formula 1, wherein $n = 1$.

29. (original) A process according to claim 28, wherein said acid chloride is thionyl chloride or oxalyl chloride to synthesize the indole-3-carbonyl chlorides according to formula 3.
30. (original) A process according to claim 28, wherein said indole-3-carbonyl chloride according to formula 3 are reacted with primary or secondary amines in the presence of an auxiliary base.
31. (original) A process according to claim 28, wherein said indole-3-carbonyl chloride is reacted with a primary or secondary amine in the presence of an excess of amine.
32. (original) A process according to claim 31, wherein the excess amine is a tertiary amine.

33. (original) A process according to claim 30, wherein indole-3-carbonyl chloride is reacted in the presence of an inorganic base.
34. (original) A process for preparing a compound according to Claim 1, comprising reacting an indole formula 4



with oxalyl chloride to form the analogous indol-3-ylglyoxylyl chloride of formula 5



reacting the compound of formula 5 with a primary or secondary amine to form the corresponding amide and eliminating a protecting group to form a compound according to formula 1, wherein n is 2.

35. (original) A process according to claim 34, wherein indol-3-ylglyoxylyl chlorides according to formula 5 are reacted with primary or secondary amines in the presence of an auxiliary base.
36. (original) A method for inhibiting PDE 4 comprising administering a sufficient amount of a compound of claim 20 to a subject to inhibit PDE 4.
37. (original) A method for treating a disease associated with the activity of eosinophils, comprising administering a therapeutically effective amount of a compound according to claim 20 to a subject in need thereof.
38. (original) A method for treating a disease associated with the activity of neutrophils comprising administering a therapeutically effective amount of a compound according to claim 20 to a subject in need thereof.
39. (original) A pharmaceutical dosage form comprising at least one compound according to claim 20 and at least one of a customary, physiologically tolerated excipient, diluent or auxiliary substance.
40. (original) A process for producing a pharmaceutical dosage form comprising admixing at least one compound according to claim 20 with a customary pharmaceutical carrier substance, a diluent or an auxiliary substance to form a therapeutically desirable pharmaceutical preparation.

41. (original) A method of treating modifying the activity of PDE 4 in a subject in need thereof comprising administering the dosage form of claim 39 to a subject in need thereof, optionally with a different therapeutically active agent.